☆ 4.7 Article

Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial

LANCET INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Public, Environmental & Occupational Health

Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model

Liangru Zhou et al.

Summary: This study evaluated the cost-effectiveness of including HPV vaccines in the Chinese immunization program. The results showed that HPV vaccines were cost-effective at the national level and in most provinces, with higher population provinces having more prevented cases and deaths. The economic situation of HPV vaccination differed at the provincial level, and provinces with limited ability to pay should seek subsidies from the state.

BMC PUBLIC HEALTH (2022)

Add to Collection

Article Infectious Diseases

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Fang-Hui Zhao et al.

Summary: The Escherichia coli-produced bivalent HPV 16 and 18 vaccine has been shown to be well tolerated and highly effective against high-grade genital lesions and persistent infection associated with HPV 16 and 18 after 66 months of follow-up. This has significant implications for cervical cancer prevention globally.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Review Immunology

Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?

Chau Quang et al.

Summary: A single dose of HPV vaccine is as effective as two or three doses in preventing HPV infection, despite lower antibody levels. Other antibody functions in addition to neutralization have not been studied for HPV vaccines. Non-neutralizing antibody functions may contribute to preventing HPV infection in single-dose vaccination.

TRENDS IN IMMUNOLOGY (2022)

Add to Collection

Article Infectious Diseases

Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study

Palmer Cody et al.

Summary: Vaccination with a 9-valent vaccine for 12 to 16 year-old girls, along with a temporary catch-up program, is projected to significantly reduce HPV-related disease cases, with an incremental cost effectiveness ratio well below a threshold of yen 5000,000/QALY.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study

Changfa Xia et al.

Summary: This study evaluated the optimal pathway towards eliminating cervical cancer in China, predicting a decrease to fewer than four new cases per 100,000 women by 2047 if the optimal pathway is adopted. By integrating multiple tailored strategies, millions of cervical cancer cases and deaths could be averted annually. Adopting the optimal pathway could lead to the elimination of cervical cancer in China by the late 2040s while saving net economic costs.

BMC MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

You-Lin Qiao et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)

Add to Collection

Review Multidisciplinary Sciences

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review

Rashidul Alam Mahumud et al.

PLOS ONE (2020)

Add to Collection

Review Medicine, General & Internal

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Melanie Drolet et al.

LANCET (2019)

Add to Collection

Article Immunology

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

Minxi Wei et al.

EMERGING MICROBES & INFECTIONS (2018)

Add to Collection

Article Medicine, General & Internal

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Warner K. Huh et al.

LANCET (2017)

Add to Collection

Article Virology

Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus

Jianhui Nie et al.

VIRUSES-BASEL (2016)

Add to Collection

Article Medicine, General & Internal

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

E. A. Joura et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Virology

Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines

Susanne Hartwig et al.

PAPILLOMAVIRUS RESEARCH (2015)

Add to Collection

Article Oncology

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Silvia de Sanjose et al.

LANCET ONCOLOGY (2010)

Add to Collection

Article Biotechnology & Applied Microbiology

Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Mark H. Einstein et al.

HUMAN VACCINES (2009)

Add to Collection

Article Immunology

Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine

Suzanne M. Garland et al.

JOURNAL OF INFECTIOUS DISEASES (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.